Skip to content

Comparison of steroids and broncodilator in treatment of bronchiolitis

COMPARISON OF INJECTABLE DEXAMETHASONE PLUS NEBULISED ADRENALINE & NEBULISED FLUTICASONE PLUS NEBULISED ADRENALINE & NEBULISED ADRENALINE ALONE IN PATIENTS OF BRONCHIOLITIS: A RANDOMISED OPEN LABEL COMPARATIVE CONTROL TRIAL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/11/010667
Enrollment
100
Registered
2017-11-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- bronchiolitis

Interventions

Intervention1: adrenaline and dexamethasone combination: adrenaline nebulisation 5 ml 6 hourly till discharge & single intramuscular dexamethasone 0.6 mg/kg dose on admission Control Intervention1: ad

Sponsors

Department of Pediatrics
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • All cases of bronchiolitis with a Respiratory Distress Assessment Instrument (RDAI) score of 4 to 15 [on a scale of 0 (mild) to 17 (severe)] • An RDAI score involves assigning a numerical value to 6 separate assessments; the sum of these scores provides an RDAI score ranging from 0 to 17, with increasing scores indicating increasing respiratory distress.

Exclusion criteria

Exclusion criteria: 1. Who received oral or inhaled corticosteroids during the preceding 2 weeks. 2. Previous diagnosis of asthma or Wheeze Associated Lower Respiratory Tract Infection. 3. Chronic disease that may affect cardiopulmonary status of the patient, such as • Bronco pulmonary dysplasia • Cystic fibrosis • Congenital heart disease • Immune deficiency. 4. Who are preterm with corrected age of less than 4 weeks at presentation 5. Congenital malformation of respiratory and cardiovascular system 6. Severe disease [clinical score > 15] requiring mechanical ventilation: a. Saturation b. Obtunded consciousness, and/or c. Progressive respiratory failure.

Design outcomes

Primary

MeasureTime frame
reduction in severity of symptomsTimepoint: 24 hours of starting drug treatment

Secondary

MeasureTime frame
reduction in duration of hospitalisationTimepoint: 8 days

Countries

India

Contacts

Public ContactDr Jayendra Gohil

Sir T. Hospital, Government Medical College

dr.atulms@gmail.com08238034085

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026